glp1ledger

Diethylpropion: What the Label Says, What the Trials Measured, and Why Europe Withdrew It

Diethylpropion (once sold as Tenuate) is a Schedule IV appetite suppressant labelled for 'a few weeks' of use. The US label, three placebo-controlled trials and the EU withdrawal of 2023, read 13 November 2026.

Ronald R · Edited by Caroline S · Published 2026-11-13

Illustration: An unbranded prescription bottle and an empty glass of water on a warm wooden kitchen counter.
Illustration

Diethylpropion is one of the oldest prescription appetite suppressants still sold in the United States, and Europe took it off the market in 2023. Its US label allows only "a few weeks" of use and describes a modest effect. Three small trials abroad measured more over 6 to 12 months. This page reports the label, those trials and the European decision, dated, and where the record stops.

Read on 13 November 2026 from the US label for diethylpropion hydrochloride tablets 25 mg (Lannett, DailyMed set 4fdbc049, revised December 2019) and the 75 mg extended-release label (Lannett, same revision), Drugs@FDA, the European Medicines Agency's referral page, and the trials cited below.

What diethylpropion is

Diethylpropion is a stimulant-type appetite suppressant. The label calls it a sympathomimetic amine "with some pharmacologic activity similar to that of the prototype drugs of this class used in obesity, the amphetamines". In Europe and Latin America the same molecule is called amfepramone.

Drugs@FDA records its first approvals in 1959: Tenuate (NDA 011722) on 6 August and Tepanil (NDA 011673) on 14 August. The 75 mg extended-release form, Tenuate Dospan, followed on 17 November 1960. It belongs to the same class of older appetite suppressants as phentermine.

What is on the market now, as Drugs@FDA lists it on the day of reading:

Product Status in Drugs@FDA
Tenuate 25 mg, Tenuate Dospan 75 mg, Tepanil, Tepanil Ten-Tab Discontinued. For Tenuate and Tenuate Dospan the record adds a Federal Register determination that they were not withdrawn for safety or effectiveness reasons
Generic 25 mg tablets Marketed (two applications, approved December 2010 and July 2011)
Generic 75 mg extended-release tablets Marketed (one application, approved October 2011)

Of the 16 diethylpropion applications in the database, three are listed as marketed. The rest are discontinued.

What the label allows

The indication is narrow. Diethylpropion is for "the management of exogenous obesity as a short-term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction", in people with a starting BMI of 30 or higher who have not responded to diet or exercise alone. Unlike phentermine's label, it gives no lower threshold for people with a BMI of 27 and a related condition.

Other limits the label prints:

  • Monotherapy only. Use with any other appetite suppressant, including over-the-counter and herbal products, is contraindicated.
  • A 4-week check. Treatment "should be continued only if the patient has satisfactory weight loss within the first 4 weeks", with "at least 4 pounds" given as an example.
  • Not after other appetite suppressants. It is not recommended for anyone who used one in the previous year.
  • Not for children. It is not recommended at age 16 and under.
  • Schedule IV. The label's dependence section says people have become psychologically dependent on it.

The two labels cover a 25 mg tablet and a 75 mg extended-release tablet. Strengths are listed as product facts, not as doses for anyone.

What the label says about how well it works

The label prints no trial table. It describes the whole class in general terms, in wording close to that of phentermine's label:

"The magnitude of increased weight loss of drug-treated patients over placebo-treated patients averages some fraction of a pound a week."

It adds that the rate of loss is greatest in the first weeks and then slows, and that "most studies cited are restricted to a few weeks duration; thus, the total impact of drug-induced weight loss over that of diet alone is unknown."

What the later trials measured

The PubMed search described below found three placebo-controlled weight trials published since 2009 that ran longer than the label's "few weeks". None was run in the United States.

Trial Population Length Diethylpropion Placebo
Cercato et al., Int J Obes 2009 (Brazil) 69 healthy adults with obesity (37 drug, 32 placebo), all on a low-calorie diet 6 months −9.8% of body weight (50 mg twice a day) −3.2%
Soto-Molina et al., Int J Clin Pharmacol Ther 2015 (Mexico) 156 adults, BMI 30 to 45 6 months −7.7 kg (75 mg a day) −1.1 kg
Suplicy et al., Int J Obes 2014 (Brazil) 174 premenopausal women with obesity across six arms (28 on diethylpropion, 29 on placebo) 52 weeks −10.0 kg (75 mg a day) −3.1 kg

Subtracting placebo, that is about 6.6 percentage points at 6 months in the first trial, 6.6 kg at 6 months in the second and 6.9 kg at one year in the third. In the Suplicy trial, 71.4% of the women on diethylpropion lost at least 5% of their weight, against 33.3% on placebo, as the abstract prints it.

The limits are in the same abstracts.

  • Small groups. Two of the three trials had 28 and 37 people on the drug. The Cercato trial enrolled "healthy" adults with obesity and its authors wrote that the drug "seems to be safe" in "a well-selected population".
  • The second half of the longest record is open-label. After 6 months, everyone in the Cercato trial received diethylpropion. At 12 months the original drug group had lost 10.6% and the group that switched from placebo 7.0%, and that difference was not significant (P = 0.07).
  • Side effects were more common on the drug. In the Suplicy trial constipation, anxiety and irritability were more frequent on diethylpropion than on placebo. Dry mouth and insomnia were the most frequent in the Cercato trial.
  • None measured heart events. These trials tracked weight, blood pressure, pulse and, in one case, heart scans in a few dozen people. They were not built to detect rare harms.

One trial compared it with phentermine directly. A 1983 study in British general practice randomised 99 patients to phentermine 30 mg or diethylpropion 75 mg a day for 12 weeks, with a 1,500-calorie diet. Its abstract reports "a significantly greater weight loss in patients treated with phentermine", most marked in the last 4 weeks, and side effects that were "comparable in the two groups". The abstract prints no weight figures, so none is given here.

An older summary points the same way on size. A 2002 meta-analysis of 108 randomised obesity-drug trials across four decades found that the placebo-subtracted loss for any single drug "never exceeded 4.0 kg". Its abstract does not give a separate figure for diethylpropion, and this page does not estimate one.

The published record is thin beside phentermine's. On 13 November 2026 PubMed held 15 records typed as randomised controlled trials with diethylpropion or amfepramone in the title or abstract. The same search for phentermine returned 54.

Beside the GLP-1 figures

For scale, with the populations named: in their own trials of adults with obesity and no diabetes, semaglutide 2.4 mg gave −14.9% against −2.4% on placebo over 68 weeks (STEP 1), and tirzepatide 15 mg gave −20.9% against −3.1% over 72 weeks (SURMOUNT-1). Those trials enrolled 1,961 and 2,539 people. The largest diethylpropion arm above had 37.

No trial was found comparing diethylpropion with a GLP-1 medicine, and the trials differ in decade, country, size and how dropouts were handled. The figures sit side by side here to show scale, not to rank the drugs. The other non-GLP-1 medicines are set out in the approved options outside the GLP-1 class and in the register of weight-loss pills.

Why Europe withdrew it

The European Medicines Agency reviewed amfepramone from February 2021. Its safety committee, the PRAC, recommended withdrawal in June 2022, confirmed that on 27 October 2022 after the companies asked for a re-examination, and the European Commission issued a binding decision on 13 January 2023. The outcome recorded on the EMA's referral page is "revocation".

The EMA's stated reasons:

  • The medicines were being used for longer than the recommended maximum of 3 months, which may raise the risk of pulmonary arterial hypertension and dependence.
  • They were being used by people with a history of heart disease or psychiatric disorders.
  • There was evidence of use during pregnancy.
  • Earlier restrictions "have not been sufficiently effective", and the committee "could not identify" further measures that would be.
  • The review "also indicated that the efficacy of amfepramone in the treatment of obesity is limited".

The decision turned on how the drug was being used in practice as much as on the drug itself. The US has made no matching decision: generic diethylpropion remains approved, and the FDA's record says the discontinued brands did not leave for safety or effectiveness reasons.

The warnings on the US label

The label shares its two best-known warnings with the rest of its class. They date from the fenfluramine era, which the phentermine side-effects page sets out in full.

  • Pulmonary hypertension. The label cites a case-control study in which appetite suppressants used for longer than 3 months were "associated with a 23-fold increase in the risk". That study, published in 1996, compared 95 patients with 355 controls and reported an odds ratio of 23.1. Its abstract says the drugs involved were "mainly derivatives of fenfluramine", a different drug that is no longer sold for weight loss.
  • Heart-valve disease. Reported with fenfluramine and dexfenfluramine. For diethylpropion alone the label says valve disease "has been very rarely reported" and that "the causal relationship remains uncertain".
  • Dependence and psychosis. The label warns that prolonged use "may induce dependence with withdrawal syndrome", and records cases of psychosis, some at recommended doses.
  • Contraindications. Pulmonary hypertension, advanced arteriosclerosis, hyperthyroidism, known hypersensitivity to this class of drug, glaucoma, severe hypertension, agitated states, a history of drug abuse, and use within 14 days of an MAO inhibitor.
  • Seizures. The label says the drug may increase convulsions in some people with epilepsy.

The adverse-reaction section is a list without rates. It names, among others, palpitations, raised blood pressure, nervousness, insomnia, dry mouth and constipation. Like phentermine's label, it gives no table showing how often each occurs.

What the record does not show

  • No long trial in the US label. The label rests on short trials and says the long-term impact over diet alone "is unknown".
  • No large trial anywhere. Two of the three modern trials put 37 and 28 people on diethylpropion. The third randomised 156 people between drug and placebo, and its abstract does not print the size of each arm.
  • One old head-to-head with phentermine, and none with a GLP-1 medicine. PubMed held 16 records naming diethylpropion or amfepramone alongside a GLP-1 medicine on 13 November 2026. They are reviews, guidelines and prescribing surveys, and none is a trial comparing the two.
  • No heart-outcome data. Nothing in the record measures heart attacks, strokes or deaths.
  • Trials were read as abstracts. Figures above are those the abstracts print.

This is where a reader should stop and ask a clinician. Whether a Schedule IV stimulant with these warnings is suitable for one person, and for how long, is a medical decision this page does not and cannot make.

Sources

  • Diethylpropion hydrochloride tablets USP 25 mg, Lannett Company, revised December 2019 — DailyMed, read 13 November 2026. Diethylpropion hydrochloride extended-release tablets 75 mg, Lannett, revised December 2019 — DailyMed.
  • Drugs@FDA via openFDA, 16 diethylpropion applications, read 13 November 2026: NDA 011722 (Tenuate), NDA 011673 (Tepanil), NDA 012546 (Tenuate Dospan), ANDA 200177, ANDA 201212, ANDA 091680.
  • European Medicines Agency, Amfepramone-containing medicinal products — referral (EMEA/H/A-31/1501), read 13 November 2026.
  • Cercato C et al., International Journal of Obesity 2009, PMID 19564877. Soto-Molina H et al., International Journal of Clinical Pharmacology and Therapeutics 2015, PMID 26073353. Suplicy H et al., International Journal of Obesity 2014, PMID 24287940. Vallé-Jones JC et al., Pharmatherapeutica 1983, PMID 6844367. Haddock CK et al., International Journal of Obesity 2002, PMID 11850760. Abenhaim L et al., NEJM 1996, PMID 8692238.
  • Wilding JPH et al., NEJM 2021, PMID 33567185 (STEP 1). Jastreboff AM et al., NEJM 2022, PMID 35658024 (SURMOUNT-1).
  • PubMed searches of 13 November 2026: (diethylpropion[Title/Abstract] OR amfepramone[Title/Abstract]) AND randomized controlled trial[pt] (15 records); phentermine[Title/Abstract] AND randomized controlled trial[pt] (54 records).

Frequently asked questions

What is diethylpropion?

A prescription appetite suppressant from 1959, chemically related to amphetamine. In the US it is sold only as a generic, as 25 mg tablets and 75 mg extended-release tablets; the Tenuate and Tepanil brands are discontinued. Its label limits it to short-term use, 'a few weeks', alongside a calorie-restricted diet.

Is diethylpropion the same as phentermine?

No. They are different molecules in the same class of older stimulant-type appetite suppressants. Both are Schedule IV, both are labelled for 'a few weeks', and their labels share the same warnings about pulmonary hypertension and heart-valve disease. One randomised comparison exists, from 1983: 99 patients over 12 weeks, with significantly greater weight loss on phentermine.

How much weight do people lose on diethylpropion?

The label gives no trial table; it says the extra loss over placebo in short trials averages 'some fraction of a pound a week'. Three later placebo-controlled trials in Brazil and Mexico measured more: 9.8% against 3.2% at 6 months, 7.7 kg against 1.1 kg at 6 months, and 10.0 kg against 3.1 kg at 52 weeks. Each trial was small, with 28 to 37 people on the drug in two of them.

Is Tenuate still available?

Not under that name in the US. Drugs@FDA lists Tenuate and Tenuate Dospan as discontinued, with a Federal Register determination that they were not withdrawn for safety or effectiveness reasons. Generic diethylpropion remains on the market.

Why was diethylpropion withdrawn in Europe?

The European Medicines Agency's safety committee found the medicines were being used for longer than the 3-month maximum, in people with heart or psychiatric disease, and in pregnancy, and that the measures meant to prevent this had not worked. It also described the benefit in obesity as limited. The European Commission's decision of 13 January 2023 revoked the authorisations across the EU.